Physician profile
Marium Ilahi
NPI 1003020645
$169,693.24
in general payments reported to CMS, 2019-2025
51 companies · $41K in 2025
The $41K reported for 2025 was more than what 95% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $34K · 2020: $8,037 · 2021: $30K · 2022: $16K · 2023: $11K · 2024: $29K · 2025: $41K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Food and Beverage: $6,646 · Travel and Lodging: $5,167 · Education: $92.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $69,613.75 |
| Food and Beverage | $6,646.37 |
| Travel and Lodging | $5,167.26 |
| Education | $92.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $92,498.73 | 2019-2025 | Evenity, Prolia, Tepezza |
| Bayer Healthcare Pharmaceuticals INC. | $40,921.76 | 2021-2025 | |
| Novo Nordisk INC | $29,142.06 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $938.65 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Abbott Laboratories | $830.10 | 2019-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $694.17 | 2019-2025 | Afrezza |
| Boehringer Ingelheim Pharmaceuticals, INC. | $506.81 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $480.68 | 2019-2025 | |
| Recordati_rare_diseases_inc. | $315.71 | 2022-2025 | Isturisa, Signifor Lar |
| Xeris Pharmaceuticals, INC. | $242.12 | 2023-2025 | Gvoke Hypopen, Recorlev, Keveyis |
| Chiesi USA, INC. | $234.71 | 2024-2025 | Mycapssa |
| Astrazeneca Pharmaceuticals Lp | $233.50 | 2019-2023 | Farxiga |
| Valeritas, INC. | $206.54 | 2019 | |
| Insulet Corporation | $200.58 | 2019-2024 | Omnipod |
| Beta Bionics, INC. | $196.27 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
Show all 51 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zealand Pharma US, INC. | $175.41 | 2021-2022 | |
| Ascensia Diabetes Care US INC. | $168.67 | 2022-2025 | |
| Corcept Therapeutics | $160.43 | 2022-2025 | Korlym |
| Radius Health, INC. | $136.92 | 2023-2025 | Tymlos |
| Dexcom, INC. | $111.22 | 2019-2023 | Dexcom G6 Transmitter |
| Novartis Pharmaceuticals Corporation | $101.79 | 2022-2024 | |
| Kyowa Kirin, INC. | $98.76 | 2023-2025 | Crysvita |
| Pfizer INC. | $92.87 | 2020-2025 | |
| Tandem Diabetes Care, INC. | $90.99 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Alexion Pharmaceuticals, INC. | $75.00 | 2025 | Strensiq |
| Medtronic, INC. | $73.29 | 2023-2025 | Minimed 780g, Intellis Adaptivestim |
| Esperion Therapeutics, INC. | $64.99 | 2021-2025 | Nexletol |
| Ultragenyx Pharmaceutical INC. | $62.59 | 2019-2020 | |
| Horizon Therapeutics Plc | $59.82 | 2023 | Tepezza |
| Amarin Pharma, INC. | $51.83 | 2019-2021 | |
| Averitas Pharma INC. | $46.89 | 2024-2025 | Qutenza |
| Amneal Pharmaceuticals LLC | $43.45 | 2025 | Unithroid |
| Janssen Pharmaceuticals, INC | $38.57 | 2019-2020 | |
| Ascendis Pharma Endocrinology INC | $38.37 | 2025 | Yorvipath |
| Abbvie INC. | $36.38 | 2021-2022 | |
| Neurocrine Biosciences, INC. | $34.13 | 2024-2025 | |
| Sequel Med Tech, LLC | $30.81 | 2025 | Twiist |
| Eisai INC. | $27.97 | 2024 | |
| Shire North American Group INC | $24.85 | 2019 | |
| Madrigal Pharmaceuticals | $23.38 | 2025 | Rezdiffra |
| Esteve Pharmaceuticals LLC | $21.25 | 2025 | Lysodren |
| Eusa Pharma (US) LLC | $18.62 | 2022 | |
| Medtronic Minimed, INC. | $18.48 | 2020 | |
| Glaxosmithkline, LLC. | $17.20 | 2025 | Arexvy, Shingrix |
| Amphastar Pharmaceuticals, INC. | $16.77 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $16.36 | 2019 | |
| Stryker Corporation | $15.84 | 2021 | |
| Amryt Pharma Holdings Ltd | $15.42 | 2023 | Mycapssa |
| Companion Medical, INC. | $14.32 | 2020 | |
| Rhythm Pharmaceuticals, INC. | $13.88 | 2023 | Imcivree |
| Convatec INC. | $13.33 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marium Ilahi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.